| 2025-04-09 |
复牌提示：
2025-04-08 16:01:00 停牌，复牌日期 2025-04-08 16:35:00
|
| 2025-03-27 |
详情>>
股本变动：
变动后总股本523.43万股
|
| 2025-03-27 |
详情>>
业绩披露：
2024年年报每股收益-15.85美元,归母净利润-3007.4万美元,同比去年增长25.11%
|
| 2025-01-28 |
详情>>
拆分方案：
每20.0000合并分成1.0000股
|
| 2024-12-10 |
股东大会：
将于2025-01-16召开股东大会
会议内容 ▼▲
- 1.To approve an amendment to the Second Amended and Restated Certificate of Incorporation (the “Restated Certificate”) to effect a reverse stock split of the issued shares of our common stock at a ratio ranging from 1 share-for-10 shares up to a ratio of 1 share-for-20 shares (without reducing the authorized number of shares of our common stock), which ratio will be selected by our board of directors and set forth in a public announcement (the “Reverse Stock Split Proposal”);
2.To transact such other business as may properly come before the Special Meeting and any adjournments or postponements of the Special Meeting.
|
| 2024-11-12 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-0.63美元,归母净利润-2208万美元,同比去年增长37.29%
|
| 2024-08-08 |
详情>>
业绩披露：
2024年中报每股收益-0.48美元,归母净利润-1423.7万美元,同比去年增长44.15%
|
| 2024-07-08 |
股东大会：
将于2024-08-12召开股东大会
会议内容 ▼▲
- 1.To approve a one-time stock option repricing and exchange program, as described in this proxy statement (the “Proxy Statement”);
2.To transact such other business as may properly come before the Special Meeting and any adjournments or postponements of the Special Meeting.
|
| 2024-05-14 |
详情>>
业绩披露：
2024年一季报每股收益-0.58美元,归母净利润-1242.9万美元,同比去年增长13.33%
|
| 2024-04-10 |
股东大会：
将于2024-05-23召开股东大会
会议内容 ▼▲
- 1.To elect three Class I directors to serve until the 2027 annual meeting of stockholders or until their successors are duly elected and qualified.
2.To approve an amendment to the Vincerx Pharma, Inc. 2020 Stock Incentive Plan to increase the number of shares authorized for issuance by 1,500,000 shares.
3.To ratify the appointment of WithumSmith+Brown, PC as our independent registered public accounting firm for the year ending December 31, 2024.
4.To transact such other business as may properly come before the Annual Meeting and any adjournments or postponements of the Annual Meeting.
|
| 2024-03-29 |
详情>>
业绩披露：
2023年年报每股收益-1.89美元,归母净利润-4015.7万美元,同比去年增长38.57%
|
| 2023-11-14 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-1.66美元,归母净利润-3520.7万美元,同比去年增长31.93%
|
| 2023-08-11 |
详情>>
内部人交易：
Seelenberger Alexander A.股份增加10500.00股
|
| 2023-08-07 |
详情>>
业绩披露：
2023年中报每股收益-1.2美元,归母净利润-2549.2万美元,同比去年增长26.84%
|
| 2023-05-11 |
详情>>
业绩披露：
2023年一季报每股收益-0.68美元,归母净利润-1434.1万美元,同比去年增长12.68%
|
| 2023-04-12 |
股东大会：
将于2023-05-25召开股东大会
会议内容 ▼▲
- 1.To elect two Class III directors to serve until the 2026 annual meeting of stockholders or until their successors are duly elected and qualified;
2.To ratify the appointment of WithumSmith+Brown, PC as our independent registered public accounting firm for the year ending December 31, 2023;
3.To transact such other business as may properly come before the Annual Meeting and any adjournments or postponements of the Annual Meeting.
|
| 2023-03-28 |
详情>>
业绩披露：
2022年年报每股收益-3.11美元,归母净利润-6536.7万美元,同比去年增长-66.3%
|
| 2022-11-10 |
详情>>
业绩披露：
2022年三季报(累计)每股收益-2.46美元,归母净利润-5172.4万美元,同比去年增长-57.53%
|
| 2022-04-12 |
股东大会：
将于2022-05-26召开股东大会
会议内容 ▼▲
- 1.to elect three Class II directors to serve until the 2025 annual meeting of stockholders or until their successors are duly elected and qualified;
2.to ratify the appointment of WithumSmith+Brown, PC as our independent registered public accounting firm for the year ending December 31, 2022;
3.to transact such other business as may properly come before the Annual Meeting and any adjournments or postponements of the Annual Meeting.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-04-12 |
股东大会：
将于2021-05-13召开股东大会
会议内容 ▼▲
- 1.to elect three Class I directors to serve until the 2024 annual meeting of stockholders or until their successors are duly elected and qualified;
2.to approve and adopt the Vincerx Pharma, Inc. 2021 Employee Stock Purchase Plan;
3.to ratify the appointment of WithumSmith+Brown, PC as our independent registered public accounting firm for the year ending December 31, 2021;
4.to transact such other business as may properly come before the Annual Meeting and any adjournments or postponements of the Annual Meeting.
|
| 2020-12-07 |
股东大会：
将于2020-12-22召开股东大会
会议内容 ▼▲
- 1.To approve the Merger Agreement, dated as of September 25, 2020 (the “Merger Agreement”), by and among LSAC, LifeSci Acquisition Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of LSAC (“Merger Sub”), Vincera Pharma, Inc., a Delaware corporation (“Vincera Pharma”), and Raquel Izumi, as representative of the stockholders of Vincera Pharma (the “Sellers”), pursuant to which Merger Sub will merge with and into Vincera Pharma, with Vincera Pharma surviving the merger and becoming a wholly-owned direct subsidiary of LSAC, and the transactions contemplated thereby (collectively with the other transactions described in the Merger Agreement, the “Business Combination”). This proposal is referred to as the “Business Combination Proposal” or “Proposal No. 1.”
2.To approve separate proposals to amend LSAC’s current Amended and Restated Certificate of Incorporation, as set forth in the Second Amended and Restated Certificate of Incorporation of LSAC, appended to this proxy statement as Annex B (the “Amended Charter”), to adopt certain material changes to be in effect upon the consummation of the Business Combination. These proposals are collectively referred to as the “Charter Amendment Proposal” or “Proposal No. 2.”
3.To approve the issuance of more than 20% of the issued and outstanding shares of LSAC’s common stock (“LSAC Shares”) pursuant to the terms of the Merger Agreement, which will result in a change of control, as required by Nasdaq Listing Rules 5635(a), (b) and (d). This proposal is referred to as the “Nasdaq Proposal” or “Proposal No. 3.”
4.To elect, effective upon the closing of the Business Combination, nine directors to serve staggered terms on our board of directors until the 2021, 2022 and 2023 annual meetings of stockholders, respectively, or until their respective successors are duly elected and qualified. This proposal is referred to as the “Director Election Proposal” or “Proposal No. 4.”
5.To approve the Vincera Pharma, Inc. 2020 Stock Incentive Plan. This proposal is referred to as the “Equity Incentive Plan Proposal” or “Proposal No. 5.”
6.To approve the adjournment of the special meeting for the purpose of soliciting additional proxies in the event LSAC does not receive the requisite stockholder vote to approve one or more proposals presented to stockholders for vote. This proposal is called the “Adjournment Proposal” or “Proposal No. 6.”
|